Literature DB >> 23135728

Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

M B Townsend1, M S Keckler, N Patel, D H Davies, P Felgner, I K Damon, K L Karem.   

Abstract

Despite the eradication of smallpox, orthopoxviruses (OPV) remain public health concerns. Efforts to develop new therapeutics and vaccines for smallpox continue through their evaluation in animal models despite limited understanding of the specific correlates of protective immunity. Recent monkeypox virus challenge studies have established the black-tailed prairie dog (Cynomys ludovicianus) as a model of human systemic OPV infections. In this study, we assess the induction of humoral immunity in humans and prairie dogs receiving Dryvax, Acam2000, or Imvamune vaccine and characterize the proteomic profile of immune recognition using enzyme-linked immunosorbent assays (ELISA), neutralization assays, and protein microarrays. We confirm anticipated similarities of antigenic protein targets of smallpox vaccine-induced responses in humans and prairie dogs and identify several differences. Subsequent monkeypox virus intranasal infection of vaccinated prairie dogs resulted in a significant boost in humoral immunity characterized by a shift in reactivity of increased intensity to a broader range of OPV proteins. This work provides evidence of similarities between the vaccine responses in prairie dogs and humans that enhance the value of the prairie dog model system as an OPV vaccination model and offers novel findings that form a framework for examining the humoral immune response induced by systemic orthopoxvirus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135728      PMCID: PMC3554095          DOI: 10.1128/JVI.02089-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  From the Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices.

Authors: 
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

2.  Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Authors:  Christine M Hughes; Frances K Newman; Whitni B Davidson; Victoria A Olson; Scott K Smith; Robert C Holman; Lihan Yan; Sharon E Frey; Robert B Belshe; Kevin L Karem; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

3.  Protein composition of the vaccinia virus mature virion.

Authors:  Wolfgang Resch; Kim K Hixson; Ronald J Moore; Mary S Lipton; Bernard Moss
Journal:  Virology       Date:  2006-09-26       Impact factor: 3.616

4.  characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak.

Authors:  Kevin L Karem; Mary Reynolds; Zach Braden; Gin Lou; Nikeva Bernard; Joanne Patton; Inger K Damon
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

5.  Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65.

Authors:  B Sodeik; G Griffiths; M Ericsson; B Moss; R W Doms
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.

Authors:  Yvette Edghill-Smith; Mike Bray; Chris A Whitehouse; David Miller; Eric Mucker; Jody Manischewitz; Lisa R King; Marjorie Robert-Guroff; Anna Hryniewicz; David Venzon; Clement Meseda; Jerry Weir; Aysegul Nalca; Virginia Livingston; Jay Wells; Mark G Lewis; John Huggins; Susan H Zwiers; Hana Golding; Genoveffa Franchini
Journal:  J Infect Dis       Date:  2005-01-04       Impact factor: 5.226

7.  A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.

Authors:  E J Wolffe; S Vijaya; B Moss
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

8.  A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein.

Authors:  Matthew C Johnson; Inger K Damon; Kevin L Karem
Journal:  J Virol Methods       Date:  2008-04-02       Impact factor: 2.014

Review 9.  Vaccinia virus transcription.

Authors:  Steven S Broyles
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

10.  Brazilian vaccinia viruses and their origins.

Authors:  Giliane S Trindade; Ginny L Emerson; Darin S Carroll; Erna G Kroon; Inger K Damon
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more
  12 in total

Review 1.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

3.  Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus).

Authors:  Patrick O Mills; Cassandra O Tansey; Sarah C Genzer; Matthew R Mauldin; Rex A Howard; Chantal A Kling; Felix R Jackson; Audrey M Matheny; Dawn M Boothe; George W Lathrop; Nathaniel Powell; Nadia Gallardo-Romero
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-03-25       Impact factor: 1.232

4.  Proteomic assessment of humoral immune responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Diane E Grill; Gregory A Poland
Journal:  Vaccine       Date:  2021-12-21       Impact factor: 3.641

Review 5.  The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.

Authors:  Julia A Tree; Helen Flick-Smith; Michael J Elmore; Caroline A Rowland
Journal:  J Immunol Res       Date:  2014-09-16       Impact factor: 4.818

Review 6.  Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution.

Authors:  Emmanuel Alakunle; Ugo Moens; Godwin Nchinda; Malachy Ifeanyi Okeke
Journal:  Viruses       Date:  2020-11-05       Impact factor: 5.048

Review 7.  The Monkeypox Outbreak and Implications for Dental Practice.

Authors:  Lakshman Samaranayake; Sukumaran Anil
Journal:  Int Dent J       Date:  2022-08-05       Impact factor: 2.607

Review 8.  Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

Authors:  Minoru Kidokoro; Hisatoshi Shida
Journal:  Vaccines (Basel)       Date:  2014-10-17

9.  Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Authors:  Jarmila Knitlova; Vera Hajkova; Ludek Voska; Jana Elsterova; Barbora Obrova; Zora Melkova
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

10.  Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.

Authors:  Julia A Tree; Graham Hall; Peter Rees; Julia Vipond; Simon G P Funnell; Allen D Roberts
Journal:  Hum Vaccin Immunother       Date:  2016-07-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.